/EINPresswire.com/ -- SAN FRANCISCO, CA--(Marketwired - May 05, 2016) - Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (NASDAQ: AEMD), is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals.

The Life Science Report: What triggered Aethlon Medical Inc., through its subsidiary Exosome Sciences, to pursue the discovery of a biomarker that could identify CTE in living individuals?

Jim Joyce: While we may be best known for our broad-spectrum therapeutic platform, our CTE-related research was triggered by the death of a former friend and teammate, who was the second person diagnosed with CTE by our colleagues at the Boston University CTE Center. This factor, and the reality that there was no way to identify CTE in the living, inspired us to take on the challenge of solving this problem.

Based on our research history and knowledge of disease-released exosomes, we thought it might be possible to identify an exosomal biomarker that could cross the blood-brain barrier with cargo that could help identify and potentially monitor neurological disease conditions. We translated our belief into the discovery of an exosomal biomarker that we call a TauSome™. In addition to CTE, we believe circulating TauSome levels could emerge as candidates to monitor other neurological disorders, such as...

Continue reading this interview: Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

Aethlon Medical Inc. paid Streetwise Reports to produce and distribute this interview. James Joyce had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Joyce and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Jim Patrick
Email contact